Cargando…

Milestones for development of tivozanib for kidney cancer therapy

Detalles Bibliográficos
Autores principales:	Crescentini, Robert, Gupta, Shilpa, Fishman, Mayer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2012
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708201/ https://www.ncbi.nlm.nih.gov/pubmed/26816699 http://dx.doi.org/10.3978/j.issn.2223-4683.2012.06.08

Ejemplares similares

Tivozanib: a novel VGFR inhibitor for kidney cancer
por: Boyle, Helen
Publicado: (2013)

Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
por: Gross-Goupil, Marine, et al.
Publicado: (2012)

Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
por: Mihály, Zsuzsanna, et al.
Publicado: (2012)

Tivozanib in the treatment of renal cell carcinoma
por: Hepgur, Mehmet, et al.
Publicado: (2013)

Tivozanib for hepatocellular carcinoma: not likely a new option
por: Estrade, Florian, et al.
Publicado: (2020)

Development of Antibody‐Directed Therapies: Quo Vadis?
por: Rodrigues, Tiago, et al.
Publicado: (2018)

Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
por: Rodenburg, RJ, et al.
Publicado: (2019)

Modulating serine palmitoyltransferase‐deoxysphingolipid axis in cancer therapy
por: Xiang, Yuancai, et al.
Publicado: (2020)

Who Has Therapy-Related AML?
por: Gale, Robert Peter, et al.
Publicado: (2017)

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
por: Cowey, C Lance
Publicado: (2013)

Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma
por: Yalcin, Suayib, et al.
Publicado: (2019)

Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis
por: Oh, Hyunwoo, et al.
Publicado: (2020)

Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma
por: Sakellakis, Minas, et al.
Publicado: (2023)

Linking metabolic and epigenetic regulation in the development of lung cancer driven by TGFβ signaling
por: Zhang, Liyi
Publicado: (2019)

Kidney injury molecule-1: a novel entry factor for SARS-CoV-2
por: Wan, Cheng, et al.
Publicado: (2021)

Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer
por: Zhou, Yunxiang, et al.
Publicado: (2023)

A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma
por: Fountzilas, Christos, et al.
Publicado: (2020)

On the road to epigenetic therapy
por: Walton, Emma L.
Publicado: (2016)

Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
por: Gupta, Shilpa, et al.
Publicado: (2011)

Tivozanib in renal cell carcinoma: a new approach to previously treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model
por: Alanazi, Wael A., et al.
Publicado: (2023)

Towards gene therapy for IPEX syndrome
por: Borna, Simon, et al.
Publicado: (2022)

FOXN1 in thymus organogenesis and development
por: Vaidya, Harsh Jayesh, et al.
Publicado: (2016)

Microbiomes as the new keystone for life sciences development
por: Udaondo, Zulema, et al.
Publicado: (2019)

ILC1: Development, maturation, and transcriptional regulation
por: Taggenbrock, Renske L.R.E., et al.
Publicado: (2022)

Neurotrophic factor therapy for Parkinson's disease: past, present and future
por: Sullivan, Aideen M., et al.
Publicado: (2016)

Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells
por: Momeny, Majid, et al.
Publicado: (2017)

Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature
por: Caquelin, Laura, et al.
Publicado: (2022)

Phage display: development of nanocarriers for targeted drug delivery to the brain
por: Bakhshinejad, Babak, et al.
Publicado: (2015)

Multiomics uncovers developing immunological lineages in human [Image: see text]
por: Stephenson, Emily, et al.
Publicado: (2021)

Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial
por: Porta, Camillo, et al.
Publicado: (2012)

SWI/SNF proteins as targets in cancer therapy
por: Schiaffino-Ortega, Santiago, et al.
Publicado: (2014)

The dual role of ROS, antioxidants and autophagy in cancer
por: Walton, Emma Louise
Publicado: (2016)

Importance of producing economic compounds to combat cancer
por: Muñoz‐Rojas, Jesús
Publicado: (2017)

High hopes and high honours for cancer immunotherapy
por: Häfner, Sophia Julia
Publicado: (2019)

Identification of progenitors capable of kidney regeneration in zebrafish
Publicado: (2011)

A role for complement blockade in kidney transplantation
por: Karpman, Diana, et al.
Publicado: (2022)

Targeting FMRP: A new window for cancer immunotherapy
por: Zhang, Yaguang, et al.
Publicado: (2023)

Balance of DNA methylation and demethylation in cancer development
por: Song, Chun-Xiao, et al.
Publicado: (2012)

Dietary intervention, a promising adjunct for cancer therapy
por: Shi, Rongchen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iph4mukhp4hqs0i7iiml5u2d1h